Patents by Inventor Pui SETO

Pui SETO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS
    Publication number: 20240084009
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: March 22, 2023
    Publication date: March 14, 2024
    Inventors: Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan LEMON
  • Single chain variable fragment CD3 binding proteins
    Patent number: 11623958
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: April 11, 2023
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan Lemon
  • PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
    Publication number: 20210100902
    Abstract: Disclosed are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed and methods of using such formulations are further provided.
    Type: Application
    Filed: September 23, 2020
    Publication date: April 8, 2021
    Inventors: Robert DUBRIDGE, Pui SETO, Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
  • PSMA Targeting Trispecific Proteins and Methods of Use
    Publication number: 20210095047
    Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 1, 2021
    Inventors: Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Pui SETO
  • Prostate specific membrane antigen binding protein
    Patent number: 10849973
    Abstract: Disclosed herein are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 1, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert Dubridge, Pui Seto, Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Bryan D. Lemon, Richard J. Austin
  • PSMA targeting trispecific proteins and methods of use
    Patent number: 10844134
    Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: November 24, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Pui Seto
  • SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS
    Publication number: 20200231672
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: January 27, 2020
    Publication date: July 23, 2020
    Inventors: Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan LEMON
  • Single chain variable fragment CD3 binding proteins
    Patent number: 10544221
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 28, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan D. Lemon
  • Single chain variable fragment CD3 binding proteins
    Patent number: 10066016
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: September 4, 2018
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan D. Lemon
  • PSMA Targeting Trispecific Proteins and Methods of Use
    Publication number: 20180162949
    Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 14, 2018
    Inventors: Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Pui SETO
  • Prostate Specific Membrane Antigen Binding Protein
    Publication number: 20180161428
    Abstract: Disclosed herein are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 14, 2018
    Inventors: Robert DUBRIDGE, Pui SETO, Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
  • SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS
    Publication number: 20170369575
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: September 14, 2017
    Publication date: December 28, 2017
    Inventors: Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan D. LEMON
  • SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS
    Publication number: 20170334997
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: May 19, 2017
    Publication date: November 23, 2017
    Inventors: Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan D. LEMON